Sertraline does not alter the β-adrenergic blocking activity of atenolol in healthy male volunteers

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 1, 1996, Pages 12-15

  Ziegler, Michael G ^a   Wilner, Keith D ^b,c  

^a UCSD MEDICAL CENTER   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ISOPRENALINE; SERTRALINE;

ADRENERGIC RECEPTOR BLOCKING; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

1-NAPHTHYLAMINE; ADRENERGIC BETA-ANTAGONISTS; ADULT; ATENOLOL; DOUBLE-BLIND METHOD; DRUG ANTAGONISM; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEADACHE; HEART RATE; HUMANS; MALE; PLACEBOS; RECEPTORS, ADRENERGIC, BETA; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STIMULATION, CHEMICAL;

EID: 0029991977     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Waal-Manning HJ. Hypertension: which β-blocker? Drugs 1976;12: 412-414
2. Halper JP, Mann JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988;153(suppl 3):87-98
3. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987:316:363-369
4. Roose SP, Glassman AH, Dalack GW. Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry 1989;50(7, suppl):12-16
5. Fisch C, Knoebel SB. Electrocardiographic findings in sertratine depression trials. Drug Investigation 1992;4:305-312
6. Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring a critical analysis. J Clin Psychiatry 1990:51(12, suppl B): 37-39
7. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986:32.481-508
8. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1991;41:225-253
9. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;35:313-334
10. Drake WM, Gordon GD. Heart block in a patient on propranolol and fluoxetine [letter]. Lancet 1994;343:425-426
11. Walley T, Pirmohamed M, Proudlove C, et al. Interaction of metoprolol and fluoxetine [letter]. Lancet 1993;341:967-968
12. Cleaveland CR, Rangno RE, Shand DR. A standardized isoproterenol sensitivity test: the effects of sinus arrhythmia, atropine, and propranolol. Arch Intern Med 1972:130:47-52
13. Lane RM, Sweeney M, Henry JA. Pharmacotherapy of the depressed patient with cardiovascular and/or cerebrovascular illness. Br J Clin Pharmacol 1994;48:256-262
14. Pillans PI, Coulter DM. Fluoxetine and hyponatremia: a potential hazard in the elderly. N Z Med J 1994;107:85-86
15. Byerley WF, McConnell EJ, McCabe RT, et al. Decreased β-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology (Berl) 1988;94:141-143